Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July 2 2003 Ties Boerma HIV Department Surveillance,

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

Antiretroviral Therapy Standard Core Indicators. Emergency Plan for AIDS Relief 2 million people reached with ART 7 million new infects prevented 10 million.
Burkina Faso Five-Year Evaluation of the Global Fund (GF5YE): Study Area 3 – Health Impact Sharing experiences in linking M&E to research linking M&E to.
Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
UNGASS Country reports Lessons learned MERG Meeting Geneva July
New Challenges in M&E Lets go. Scaling Up Monitoring & Evaluation Strategic Information PROGRAM GUIDANCE RESULT NEEDS OPPORTUNITIES Resources New directions.
TB/HIV Research Priorities in Resource- Limited Settings Where we are now and some suggestions for where to go Paul Nunn February 2005.
February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
TB/HIV Research Priorities: TB Preventive Therapy.
Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
Priority Issues and Strategic Information Needs for Kenya in scaling up ART.
Improving diagnosis TB laboratory strengthening.
World Health Organization Department of HIV/AIDS Estimates of ARV Treatment Needs
February Dakar, Senegal
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
GIS INTEGRATION IN HEALTH CASE OF RWANDA Uwayezu Gilbert and Murenzi Daniel.
European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
Expert consultation on TB/HIV research priorities, February 2005 Mesdames et messieurs, soyez les bienvenus On behalf of the organizing committee.
Part A/Module A1/Session 4 Part A: Module A1 Session 4 Comprehensive Care for People Living with HIV/AIDS (PLHA)
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
Prevention of Mother-to-Child Transmission of HIV in Ghana
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Methods for Estimating Global Resource Needs for HIV/AIDS John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,
Kevin Fenton, MD, PhD, FFPH Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention.
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
HIV Patient ART Monitoring Meeting: International Conference Centre, Geneva March 2004 Defining the variables.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Unit 10. Monitoring and evaluation
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Nassau, The Bahamas 18 November 2011 The Status Of The HIV Epidemic In The Caribbean: Implications for research, surveillance and priority setting at country.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Resource Needs Model Rachel Sanders October 28 th, 2010.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July
Monitoring &Evaluation System in Health Program. Brief overview of NACP Reporting units and quality aspects Data sets Learning/ Analysis of the data sets.
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
TB/HIV COLLABORATION IN GHANA Dr. Nii Nortey Hanson – Nortey National TB Control Programme Accra.
From Mekong to Bali: The scale up of TB/HIV collaborative activities in Asia- Pacific, August 8-9, 2009 Denpasar, Bali, Indonesia "TB/HIV Monitoring and.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.
HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
Downloaded from Partnership for Implementation of workplace Programs Emmanuel Alhassan NACA ICASA, Abuja,
Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.
STRATEGIC INFORMATION FOR ACTION IN VIET NAM 6 th Viet Nam National Scientific Conference 24 November 2015 Ha Noi, Viet Nam Amitabh Bipin SUTHAR, PharmD,
Strengthening Integration between RMNCH and HIV services Nuhu Yaqub WHO Tanzania.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
33 MEETING OF THE UNAIDS PROGRAMME COORDINATING BOARD GENEVA, SWITZERLAND DECEMBER 2013 THE EQUITY DEFICIT: UNEQUAL AND UNFAIR ACCESS TO HIV TREATMENT,
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
Strategic Information on ART Scale up Kevin O'Reilly Department of HIV/AIDS WHO.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Ladies and gentlemen, On behalf of my country, the Republic of Côte d’Ivoire, I want to tell you how very pleased I am to be part of this high-level meeting,
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Fabienne Hariga Senior Adviser, HIV/AIDS Section
Monitoring and Evaluation Frameworks
The Debswana Anti Retroviral Therapy Programme
Antiretroviral therapy coverage in sub-Saharan Africa,
Patrick Brenny, UNAIDS RST-WCA
Cotrimoxazole Prophylaxis in HIV positive individuals Group A
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Presentation for Second Meeting of the Global TB/HIV Working Group
Care for those with HIV/TB: HBC, palliative care, CPT, IPT, STI, nutritional and psychological support. All the interventions should be considered within.
South Africa: From ProTest to Nationwide Implementation
The STOP TB Strategy – 2009 VISION: A TB-free world
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance, Research and Monitoring & Evaluation

OBJECTIVES OF THE MEETING Assess the needs for strategic information in the context of ART programmes Share experiences in developing monitoring and evaluation systems and other strategic information efforts Explore methods and techniques that can be considered for monitoring ART programmes Develop a list of priority strategic information issues faced by national programmes and large-scale projects and explore ways to address those issues

Primary goals of ART programmes - Enhance the length and quality of life of persons with advanced HIV infection - Reduce HIV transmission as a non-conventional prevention tool ** Provision ARV drugs to those who need it - HIV infected persons with advanced infection - Public health approach to delivery of drugs Inclusion of 12 ARVs on WHO Essential Drugs list Standardised combination ARV in poor settings: first and second-line regimens Recommend minimum requirements for safe monitoring of therapy Beginning of a district approach in countries Other elements and links HIV Testing and Counselling Treatment and prophylaxis of opportunistic infections Link with TB Control, PMTCT and Care&Support programmes DEFINING ART PROGRAMMES **Blower and Farmer, AIDScience, 2003, 3 (11)

Treatment as a disease control measure (e.g. tuberculosis) Reduced transmission Effective Case Management Case detection, Case treatment Case holding Therapeutic benefits for infected individuals - cure

ARV Treatment as a disease control measure Reduced transmission Effective Case Management Case detection, Case treatment Case holding Therapeutic benefits for infected individuals More HIV testing & counselling Stigma reduction Reduction in infectiousness of people on treatment Behavioural disinhibition Diverting resources from prevention Longer duration of infectiousness - + O F T A H C E T R O R S

DEVELOPING PROGAMMES Different models in different settings Models not yet well defined - roadmap Strategic information can play an important guiding role in the development of appropriate and effective programmes

STRATEGIC INFORMATION

WHAT DO WE MEAN BY STRATEGIC INFORMATION? DATA KNOWLEDGE ÎNFORMATION ACTION Analysis Understanding Application Generating information and knowledge to influence policy making, programme action, and research Assessment

WHAT KIND OF INFORMATION DO WE NEED? Needs, resources, access, coverage What are and will be the needs for treatment? What resources are available and what will be needed? How many have access? Who has access? Programme Monitoring & Evaluation Is the programme performing according to plans? Is the programme able to contain drug resistance development? Does the programme make a difference? Is it achieving its goals? How much does it cost and how cost effective is it? Patient monitoring Operations Research How can programme implementation be improved? What are the best models of implementation? What can be done to improve health systems? Research Can we provide more efficacious and more effective interventions? What impact do programmes have?

Needs, resources, access, coverage

Trends in Number of People Living with HIV infection by WHO Region mln people living with HIV 5 mln new infections 3.1 mln deaths SEARO <1%

Heterogeneity in the African epidemic Median HIV prevalence (%) in antenatal clinics in cities by subregion in sub-Saharan Africa,

Strategic Information - Urban-Rural and Gender HIV prevalence among years by place residence for men and women, Burundi, % of the population 60% of HIV cases

Access to ARV Treatment for HIV: The 3 By 5 goal

Drug prices Resource availability Global Fund World Bank MAP US Government Health system capabilities STRATEGIC INFORMATION ON RESOURCES Resource needs GAPS

HOW MANY NOW? (COVERAGE) Build national monitoring systems Global coverage survey of key informants 2003 Global district access survey 2004

MONITORING AND EVALUATION

Input Process Output Outcome Impact A FRAMEWORK for Monitoring and Evaluation for ARV Therapy Programmes Resources Staffing Policies Training Logistics Management Education etc. Services available (testing & counseling, ART, lab) Quality services Public understands ART People on Treatment Knowledge HIV status Stigma lower Behavioural change Survival Quality of life HIV/STI transmission reduced

Input Process Output Outcome Impact DATA COLLECTION for Monitoring and Evaluation HIV/STI surveillance, surveys Patient monitoring Household Surveys Facility surveys Patient monitoring Programme Monitoring

Input Process Output Outcome Impact M&E of ARV treatment programmes (with examples of indicators) Existence of national policies on ARV (UNGASS) Access % of districts / facilities with ARV treatment services (% of people in need of ARV with access within one hour travel time) Quality % of designated facilities providing ARV treatment in line with national standards (trained person, drugs in stock, treatment register used, treatments correct, lab support) Coverage % of people with advanced HIV infection receiving ARV combination therapy ( UNGASS) Impact Survival rates among HIV infected (at 2 years)

Percent of people with advanced HIV infection receiving ARV combination therapy (UNGASS) Number of people receiving treatment at the start of the year + Number of people who commenced in the last 12 months - Number of people who discontinued treatment in the 12 months Number of people with advanced HIV infection (based on estimated number of deaths in the same and following year) * 100 Access to ARV through: private sector, NGOs, employers, research community, public sector

Way Forward: development of guidance and tools to countries in developing M&E system Patient monitoring Programme monitoring Treatment register: (Starting treatment, Substitute drugs because of toxicity, Switch regimen because of treatment failure, Stopping treatment) and link this to the supply of drugs –Individual? Electronic? Facility records? Adherence to therapy Assess treatment outcomes: morbidity and mortality reporting (AIDS case definitions, survival analysis)

Way Forward: development of guidance and tools to countries in developing M&E system Develop reporting simple systems to monitor at the facility, district, regional/provincial and national levels Develop a simple tool for a facility survey to assess availability & quality, including laboratory support Develop a simple tool to assess community and client preparedness perspectives on ARV treatment (including interaction care-prevention) - operational research

Operations Research

Building Programmes: Pilot Study Model Research proves intervention works Pilot studies Develop programmes

Building Programmes: Scale Up Model Research proves intervention works Lesson learned in other countries Develop programmes Operational research

Operations research issues: examples Integrated systems to track patients, drugs and fees at point of delivery Appropriate human resource planning for ARV programmes Working with the private sector – the franchising approach Setting and supervising/regulating health standards in ART programmes Equity of access to ART programmes Measurement of costs of implementing ART programmes Assessment of community preparedness and readiness Measurement of stigma and discrimination in the context of ART programmes Strategies to maximize long-term adherence (chronic disease model) Delivering and sustaining ART in drug-using communities

Research CLINICAL When to start treatment What therapies to be used What methods for patient monitoring Operations research? Clinical trials, also observational designs and comparative cohort studies may be used OUTCOME Survival, health, quality of life of patient but also children, family, community PREVENTION Longitudinal studies with trends in behaviour, stigma, risk perception etc.

Global partnerships and major initiatives Session 2 Pulling together and using strategic information Stop TB PMTCT+ TAP World Bank WHO IAS Resistance monitoring network Global Fund

WHOs role - Building Evidence for Effective ART programmes (The Build Up Initiative) WHO to assist health sector in building effective progammes, link research and programmes FUNCTIONS Focus on coordination of programme oriented research that is conducted while programmes are being developed Initiate and guide multi-country operational research initiatives Support to in-depth research studies (clinical, outcome, prevention) Ensure rapid and wide use of results for policies and programmes in countries and globally OPERATIONAL FEATURES Partnership with donors and countries - steering committee Linking with networks (drug resistance, ITAC, clinical research etc.) Secretariat at WHO OR multi-country research initiatives

Agenda Session 3 Assessment of needs and programme inputs Session 4 Assessment of programme outcome (clinical and economic) Session 5 Country and project experiences in M&E systems and strategic information efforts Session 6 Using technology to monitor ART programmes Session 7 Monitoring individual and community knowledge, attitudes and behaviours Session 8 Developing the priority strategic information issues for national programmes and large-scale projects

EXPECTED OUTCOMES Consensus on a list of priority strategic information issues and how to address these issues - A clear picture of immediate and mid-term country strategic information needs Increased understanding and partnership globally with strong input from countries to support the development of sound monitoring and evaluation systems for ART programmes